

Title (en)
BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS

Title (de)
BINDUNGSDOMÄNE-IMMUNOGLOBULIN-FUSIONSPROTEINE

Title (fr)
PROTEINES DE FUSION D'IMMUNOGLOBULINE DE DOMAINE DE LIAISON

Publication
EP 1361892 A4 20041013 (EN)

Application
EP 02707519 A 20020117

Priority

- US 0201487 W 20020117
- US 76520801 A 20010117

Abstract (en)
[origin: WO02056910A1] The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.

IPC 1-7
C12N 15/62; A61K 39/395; C07H 21/04; C07K 16/44; C12N 15/13; C12N 5/10; C12N 15/00

IPC 8 full level
C12N 15/09 (2006.01); **A61K 38/00** (2006.01); **A61K 38/16** (2006.01); **A61K 39/00** (2006.01); **A61P 3/10** (2006.01); **A61P 5/14** (2006.01); **A61P 21/04** (2006.01); **A61P 25/00** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/06** (2006.01); **C07K 16/28** (2006.01); **C07K 16/30** (2006.01); **C07K 16/42** (2006.01); **C07K 19/00** (2006.01); **C12N 5/10** (2006.01); **C12N 15/62** (2006.01); **C12P 21/02** (2006.01)

CPC (source: EP KR)
A61P 1/04 (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/14** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/06** (2017.12 - EP); **A61P 21/04** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/2803** (2013.01 - EP); **C07K 16/2896** (2013.01 - EP); **C07K 16/30** (2013.01 - EP); **C07K 19/00** (2013.01 - KR); **A61K 2039/505** (2013.01 - EP); **C07K 2317/52** (2013.01 - EP); **C07K 2317/622** (2013.01 - EP); **C07K 2317/732** (2013.01 - EP); **C07K 2317/734** (2013.01 - EP); **C07K 2319/00** (2013.01 - EP)

Citation (search report)

- [A] WO 0044777 A1 20000803 - IMCLONE SYSTEMS INC [US], et al
- [A] US 5844093 A 19981201 - KETTLEBOROUGH A CATHRINE [GB], et al
- [X] WO 9221755 A1 19921210 - GENENTECH INC [US]
- [X] EP 0586002 A2 19940309 - CENTRO INMUNOLOGIA MOLECULAR [CU]
- [X] US 5736137 A 19980407 - ANDERSON DARRELL R [US], et al
- [X] US 5776456 A 19980707 - ANDERSON DARRELL R [US], et al
- [XY] WO 9509917 A1 19950413 - UNIV CALIFORNIA [US]
- [XY] WO 9405690 A1 19940317 - SMITHKLINE BEECHAM CORP [US], et al
- [X] HAYDEN M S ET AL: "Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.", THERAPEUTIC IMMUNOLOGY. ENGLAND JAN 1994, vol. 1, no. 1, January 1994 (1994-01-01), pages 3 - 15, XP009023719, ISSN: 0967-0149
- [A] PARK S S ET AL: "Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens.", MOLECULAR IMMUNOLOGY. ENGLAND DEC 2000, vol. 37, no. 18, December 2000 (2000-12-01), pages 1123 - 1130, XP002266827, ISSN: 0161-5890
- [X] MUÑOZ E ET AL: "The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3.", INTERNATIONAL IMMUNOLOGY. FEB 1998, vol. 10, no. 2, February 1998 (1998-02-01), pages 97 - 106, XP002288227, ISSN: 0953-8178
- [X] MARTIN S ET AL: "EFFICIENT NEUTRALIZATION AND DISRUPTION OF RHINOVIRUS BY CHIMERIC ICAM-1/IMMUNOGLOBULIN MOLECULES", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 67, no. 6, June 1993 (1993-06-01), pages 3561 - 3568, XP001070889, ISSN: 0009-7330
- [X] GILLILAND L K ET AL: "RAPID AND RELIABLE CLONING OF ANTIBODY VARIABLE REGIONS AND GENERATION OF RECOMBINANT SINGLE CHAIN ANTIBODY FRAGMENTS", 1996, TISSUE ANTIGENS, MUNKSGAARD, COPENHAGEN, DK, PAGE(S) 1-20, ISSN: 0001-2815, XP000574883
- [X] STEVENSON G T ET AL: "Mechanisms in removal of tumor by antibody.", CELL BIOPHYSICS. 1994, vol. 24-25, 1994, pages 45 - 50, XP009033358, ISSN: 0163-4992
- [X] ANDERSON ET AL: "Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma", 1997, BIOCHEMICAL SOCIETY TRANSACTIONS, COLCHESTER, ESSEX, GB, PAGE(S) 705-708, ISSN: 0300-5127, XP002078838
- See references of WO 02056910A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 02056910 A1 20020725; AU 2002241922 A2 20020730; AU 2002241922 B2 20071025; CA 2433877 A1 20020725; CA 2433877 C 20141118; CN 101684158 A 20100331; CN 1268394 C 20060809; CN 1486192 A 20040331; CN 1911965 A 20070214; CN 1911965 B 20130529; EP 1361892 A1 20031119; EP 1361892 A4 20041013; EP 2316951 A1 20110504; EP 2706116 A1 20140312; IL 156955 A0 20040208; IL 202255 A0 20100616; JP 2004525620 A 20040826; JP 2008260781 A 20081030; JP 2010209112 A 20100924; JP 2013049707 A 20130314; KR 100927261 B1 20091118; KR 20030066821 A 20030809; MX PA03006358 A 20041202; NZ 527591 A 20060428; PL 364623 A1 20041213; RU 2003125266 A 20050120; RU 2420537 C2 20110610; ZA 200305098 B 20040930

DOCDB simple family (application)

US 0201487 W 20020117; AU 2002241922 A 20020117; CA 2433877 A 20020117; CN 02803820 A 20020117; CN 200610093692 A 20020117; CN 200910165059 A 20020117; EP 02707519 A 20020117; EP 10182383 A 20020117; EP 13178315 A 20020117; IL 15695502 A 20020117; IL 20225509 A 20091122; JP 2002557417 A 20020117; JP 2008159145 A 20080618; JP 2010126883 A 20100602; JP 2012257362 A 20121126; KR 20037009474 A 20020117; MX PA03006358 A 20020117; NZ 52759102 A 20020117; PL 36462302 A 20020117; RU 2003125266 A 20020117; ZA 200305098 A 20030630